Clinical Trials Logo

Fungal Infection clinical trials

View clinical trials related to Fungal Infection.

Filter by:

NCT ID: NCT06417983 Not yet recruiting - Fungal Infection Clinical Trials

Topical Application of Essential Oils to Treat Onchomycosis

NailFungus
Start date: May 30, 2024
Phase:
Study type: Observational

Patients with documented onychomycosis of one or more toe nails will be treated with a daily application of a topical lacquer containing several essential oils.

NCT ID: NCT06025682 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

INO-FIRST
Start date: April 4, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about infectious complications in patients affected by B-cell acute lymphoblastic leukemia treated with inotuzumab-ozogamicin (INO). The main question it aims to answer is: • incidence of infectious complications (bacterial, fungal, viral) in patients receiving inotuzumab ozogamicin up to 60 days after the end of treatment

NCT ID: NCT05876962 Not yet recruiting - Fungal Infection Clinical Trials

The Impact of Rapid Diagnostic Methods in the Diagnosis of Fungal Infections in Intensive Care Units of Assiut University Hospital

Start date: January 2024
Phase:
Study type: Observational

The diagnosis of invasive fungal disease remains challenging in the clinical laboratory. The use of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) for the identification of filamentous fungi as well as its application for antifungal resistance testing and strain typing Will be evaluated.

NCT ID: NCT05814432 Not yet recruiting - Immunosuppression Clinical Trials

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

Phase III trial evaluating the safety and efficacy of a single high dose (10 mg/kg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg/kg of liposomal amphotericin B for two weeks) (INDUCTION trial).

NCT ID: NCT05642624 Completed - Fungal Infection Clinical Trials

The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock

Start date: February 28, 2019
Phase:
Study type: Observational

To explore the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis/septic shock;To compare the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis and septic shock.

NCT ID: NCT05368948 Not yet recruiting - Fungal Infection Clinical Trials

The Assessment of Antimicrobial Peptides Against Fungal Infection

Start date: December 2022
Phase:
Study type: Observational

- Identification of different types of fungi. - Determine sensitivity the profile and the resistance pattern of the clinical isolates against antifungal. - Determine the antifungal effects of defensin, cathelicidin and histatins and their effects on biofilm formation and resistant isolates.

NCT ID: NCT05283278 Completed - Fungal Infection Clinical Trials

Effect of Administration of Combined Enteral Lactoferrin and Probiotic On Invasive Fungal Infections In Preterm Neonates

Start date: February 10, 2020
Phase: Phase 1
Study type: Interventional

The risk for invasive fungal infections is high in very low birth weight (VLBW) infants (< 1500 g) and highest for infants born at the youngest gestational ages who survive past the immediate postnatal period. Invasive fungal infections (IFIs) represent an increasing cause of severe morbidity and mortality in most neonatal intensive care units. Lactoferrin (LF) is secreted by epithelial cells into exocrine fluids: seminal fluid, tears, saliva, uterine secretions, and milk. LF is involved in innate immunity mechanisms with several documented anti-infective properties, including antifungal activity. Probiotics are microorganisms that are believed to provide health benefits when consumed. It is possible to adopt measures to modify the flora in our bodies and to replace the harmful microbes by useful microbes. There are certain commercially available strains of probiotic bacteria from the Bifido bacterium and Lactobacillus genera when taken by mouth in daily doses possess treatment efficacy

NCT ID: NCT05235711 Recruiting - Fungal Infection Clinical Trials

The Role Of Interferon-gamma In Immune Responses To Invasive Candidiasis

Start date: February 10, 2022
Phase:
Study type: Observational

The purpose of the study is to investigate the role of the human immune response to candidemia/invasive candidiasis as it relates to the cytokine interferon-gamma.

NCT ID: NCT05202366 Recruiting - Onychomycosis Clinical Trials

An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

Start date: February 8, 2022
Phase:
Study type: Observational

The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s). This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application follow-up at Week 24. The applications could be extended for an additional 12 weeks based on PI's observations. Approximately 15 subjects will be enrolled and subjected to application of CGB-400 Topical Gel. Subjects must be at least 18 years of age and will be selected by the concerned PI.

NCT ID: NCT05152875 Completed - Clinical trials for Bronchopulmonary Dysplasia

Relationship Between Fungal Colonization and Severe Bronchopulmonary Dysplasia

FunDyP
Start date: March 21, 2022
Phase:
Study type: Observational

The aim of this study is to determine if fungal colonization is associated to severe bronchopulmonary dysplasia in premature infants less than 29 weeks of gestation, and to determine if an association exists between fungal colonization and complications of prematurity and death.